Progesterone receptor status in determining the prognosis of estrogen receptor positive/HER2 negative breast carcinoma patients

dc.authorid0000-0002-6901-2646
dc.authorid0000-0001-5279-0903
dc.authorid0000-0001-9519-6373
dc.authorid0000-0002-6839-2632
dc.contributor.authorBal, Öznur
dc.contributor.authorArslan, Ülkü Yalçıntaş
dc.contributor.authorDurnalı, Ayşe
dc.contributor.authorÜyetrk, Ümmügül
dc.contributor.authorDemirci, Ayşe
dc.date.accessioned2021-06-23T19:42:34Z
dc.date.available2021-06-23T19:42:34Z
dc.date.issued2015
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractPurpose: To evaluate the impact of progesterone receptor (PR) status on estrogen receptor (ER)-positive and HER2-negative breast cancer. Methods: A total of 1673 operable breast cancer patients, diagnosed from June 1984 to June 2011 were retrospectively reviewed and 400 patients with ER-positive and HER2-negative tumors were identified and evaluated. ER-positive and HER2-negative patients were classified into two groups: group A: ER+/PR-/HER2- and group B: ER+/PR+/HER2- according to PR status. Results: Median follow-up was 14.2 years (range 10.1-18.2). The ratio of postmenopausal patients was significantly higher in group A (68.2%, p=0.015). Grade 1 tumor and stage I disease were significantly higher in group B (15%, p=0.007 and 15%, p=0.005, respectively). Mean overall survival (OS) and disease free survival (DFS) were significantly better in group B (15.3 +/- 1.5 years vs 8.7 +/- 0.8 years, p=0.032; 10.5 +/- 1.6 years vs 5.7 +/- 0.5 years, p=0.022) as compared with group A. Relative risk for recurrence and death were two-fold higher in group A (p=0.05 and p=0.01, respectively). Conclusion: PR status exerts a significant impact on prognosis of ER+/HER2- breast cancer.en_US
dc.identifier.endpage34en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue1en_US
dc.identifier.pmid25778292en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage28en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/8536
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000351566500004
dc.identifier.volume20en_US
dc.identifier.wosWOS:000351566500004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÜyetrk, Ümmügül
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectEstrogen Receptoren_US
dc.subjectHER2en_US
dc.subjectProgesterone Receptoren_US
dc.subjectPrognosisen_US
dc.titleProgesterone receptor status in determining the prognosis of estrogen receptor positive/HER2 negative breast carcinoma patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
oznur-bal.pdf
Boyut:
467.94 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text